RushNet Announces Late Stage Acquisition Talks with Cannabis Growers
November 29, 2018 at 10:30 am IST
Share
RushNet, Inc. (OTCPK:RSHN) announced it has reached the final stages of negotiations with various licensed cannabis grow operations with multiple locations in Colorado and in California with combined revenue exceeding $62 million. Due to the sensitivity of these talks, further details will be revealed as each acquisition is consummated. Dr. Richard E Goulding, Chairman of the Board and Chief Medical Officer of RushNet, stated, Implementing our synergistic acquisition model, these acquisitions are an important step for us to become a substantial player in the cannabis sector. We are exploring opportunities available to us to aggressively expand the size of our operations and are looking at multiple acquisition targets we hope to announce soon.
RushNet, Inc. operates under the name HeliosDX. HeliosDX is a national clinical reference laboratory offering high-complexity urine drug testing (UDT), behavioral drug testing, allergy droplet cards, oral fluids, and infectious disease (PCR). The Company provides management services and insurance billing services principally to clinical reference laboratories. It provides PGX testing through Leo Partners. It provides oral fluid toxicology testing for a range of drugs. The Quantisal Collection Procedure makes taking the sample quick and easy. HeliosDX also offers a preliminary 10-panel plus adulteration detection screen, as well as confirmation testing via its comprehensive toxicology panel. Its subsidiaries include Chattahoochee Physicians Laboratory Services, LLC; doing business as HeliosDx and Grandeza Healthcare Consultants, LLC.
RUSHNET, INC. 
